CANCER 2026 Patrick Connerty
Childrens Cancer Institute Australia, NSW, Australia
Presentations this author is a contributor to:
Integrating venetoclax sensitivity profiling and high-throughput drug screening to inform personalised therapy in paediatric acute myeloid leukaemia (133063)
1:00 PM
Mehrin Zaman
Session 4: Molecular drivers of hematopoietic malignancies
Utilising Cas gene editing systems to identify non-coding lncRNA dependencies in high-risk MLL-rearranged acute myeloid leukaemia (#158)
5:40 PM
Steven He
Welcome Reception & Poster Session 1